MCID: STR020
MIFTS: 55

Strabismus

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Strabismus

MalaCards integrated aliases for Strabismus:

Name: Strabismus 56 12 74 54 6 15 71
Strabismus, Susceptibility to, 1 56 13
Strabismus, Susceptibility to 56
Susceptibility to Strabismus 29
Strabismus 1 56

Characteristics:

OMIM:

56
Inheritance:
familial, but no simple mendelian inheritance established


Classifications:



External Ids:

Disease Ontology 12 DOID:540
OMIM 56 185100
ICD9CM 34 378.7
ICD10 32 H50.8 H50.9
MedGen 41 C1861449
UMLS 71 C0029831 C0038379

Summaries for Strabismus

OMIM : 56 Strabismus, a misalignment of the eyes also referred to as 'squint,' is one of the most common ocular disorders in humans, affecting 1 to 4% of the population. It is frequently associated with amblyopia (uniocular visual neglect) (Parikh et al., 2003). Strabismus is also a feature of several syndromes, including congenital fibrosis of extraocular muscles (see, e.g., CFEOM1; 135700), Duane retraction syndrome (126800), and chronic progressive external ophthalmoplegia with myopathy (530000). (185100)

MalaCards based summary : Strabismus, also known as strabismus, susceptibility to, 1, is related to pathologic nystagmus and myelomeningocele, and has symptoms including ophthalmoplegia, spasm of conjugate gaze and anomalies of divergence. An important gene associated with Strabismus is TYR (Tyrosinase). The drugs Dexmedetomidine and Ketamine have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and thyroid, and related phenotypes are microtropia and Decreased NANOG protein expression

Wikipedia : 74 Strabismus is a condition in which the eyes do not properly align with each other when looking at an... more...

Related Diseases for Strabismus

Diseases in the Strabismus family:

Rare Disorder with Strabismus

Diseases related to Strabismus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 672)
# Related Disease Score Top Affiliating Genes
1 pathologic nystagmus 32.4 TYR KIF7 GNB1 GALC
2 myelomeningocele 31.5 VANGL2 VANGL1 SLC2A1
3 alacrima, achalasia, and mental retardation syndrome 31.3 STXBP1 SLC2A1 MPP4 MED13L GNB1 DHX30
4 microcephaly 30.9 STXBP1 SPART SLC2A1 POGZ FOXG1 DHX30
5 anencephaly 30.8 VANGL2 VANGL1 KIF7
6 autism 30.6 TMCO1 STXBP1 POGZ PCDH19 FOXG1 DHX30
7 mechanical strabismus 12.7
8 mental retardation, anterior maxillary protrusion, and strabismus 12.6
9 hemifacial hyperplasia with strabismus 12.5
10 ptosis, strabismus, and ectopic pupils 12.5
11 speech development, delayed, with facial asymmetry, strabismus, and transverse earlobe crease 12.3
12 exotropia 12.2
13 paralytic squint 12.2
14 esotropia 12.2
15 syndromic disorder with strabismus 12.2
16 severe intellectual disability-hypotonia-strabismus-coarse face-planovalgus syndrome 12.1
17 rare genetic disorder with strabismus 12.1
18 syndromic genetic disorder with strabismus 12.1
19 rare disorder with strabismus 12.1
20 craniostenosis with strabismus 12.1
21 mehes syndrome 11.9
22 mental retardation, autosomal recessive 36 11.7
23 tukel syndrome 11.6
24 hypertropia 11.6
25 white-sutton syndrome 11.6
26 amblyopia 11.6
27 fourth cranial nerve palsy, familial congenital 11.6
28 abducens nerve disease 11.6
29 duane retraction syndrome 11.5
30 crouzon syndrome 11.5
31 retinoblastoma 11.5
32 farsightedness 11.4
33 fibrosis of extraocular muscles, congenital, 2 11.4
34 3mc syndrome 11.4
35 mcpherson robertson cammarano syndrome 11.4
36 microdontia hypodontia short stature 11.4
37 singh chhaparwal dhanda syndrome 11.4
38 brown syndrome 11.4
39 retinoschisis 1, x-linked, juvenile 11.4
40 ocular albinism 11.4
41 hypotropia 11.4
42 duane retraction syndrome 1 11.3
43 ocular motility disease 11.3
44 3-methylglutaconic aciduria, type iii 11.3
45 cyclotropia 11.3
46 krauss herman holmes syndrome 11.3
47 fibrosis of extraocular muscles, congenital, 1 11.3
48 moebius syndrome 11.3
49 coloboma of macula 11.2
50 apert syndrome 11.2

Graphical network of the top 20 diseases related to Strabismus:



Diseases related to Strabismus

Symptoms & Phenotypes for Strabismus

Human phenotypes related to Strabismus:

31
# Description HPO Frequency HPO Source Accession
1 microtropia 31 HP:0031724

Symptoms via clinical synopsis from OMIM:

56
Eyes:
strabismus
microtropia
cyclic strabismus (periodic esotrophia)

Clinical features from OMIM:

185100

UMLS symptoms related to Strabismus:


ophthalmoplegia, spasm of conjugate gaze, anomalies of divergence

GenomeRNAi Phenotypes related to Strabismus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased NANOG protein expression GR00184-A-3 9.02 KIF7 MED13L
2 Decreased NANOG protein expression GR00184-A-6 9.02 KIF7 MED13L NALCN

MGI Mouse Phenotypes related to Strabismus:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 ADGRG1 FOXG1 GALC GNB1 NALCN PCDH19
2 cellular MP:0005384 10.11 ADGRG1 FOXG1 GALC GNB1 KIF7 MPP4
3 growth/size/body region MP:0005378 10 DHX30 FOXG1 GALC GNB1 KIF7 POGZ
4 mortality/aging MP:0010768 10 DHX30 FOXG1 GALC GNB1 KIF7 NALCN
5 embryo MP:0005380 9.97 DHX30 FOXG1 GNB1 KIF7 NALCN SLC2A1
6 nervous system MP:0003631 9.86 ADGRG1 DHX30 FOXG1 GALC GNB1 KIF7
7 skeleton MP:0005390 9.28 FOXG1 GALC GNB1 KIF7 STXBP1 TMCO1

Drugs & Therapeutics for Strabismus

Drugs for Strabismus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 160)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
2
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
3
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
4
Desflurane Approved Phase 4 57041-67-5 42113
5
tannic acid Approved Phase 4 1401-55-4
6
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
7
Fluorometholone Approved, Investigational Phase 4 426-13-1 9878
8
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
9
Rimexolone Approved Phase 4 49697-38-3 39507
10
Iodine Approved, Investigational Phase 4 7553-56-2 807
11
Povidone-iodine Approved Phase 4 25655-41-8
12
Povidone Approved Phase 4 9003-39-8
13
Brinzolamide Approved Phase 4 138890-62-7 68844
14
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
15
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
16
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
17 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
18
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
19
leucovorin Approved Phase 4 58-05-9 6006 143
20
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
21
rituximab Approved Phase 4 174722-31-7 10201696
22
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
23
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
24 Adrenergic alpha-Agonists Phase 4
25 Excitatory Amino Acid Antagonists Phase 4
26 Anesthetics, Dissociative Phase 4
27 Anesthetics, General Phase 4
28 Adrenergic Agents Phase 4
29 Analgesics, Non-Narcotic Phase 4
30 Hypnotics and Sedatives Phase 4
31 Adrenergic Agonists Phase 4
32 Anesthetics, Intravenous Phase 4
33 Ophthalmic Solutions Phase 4
34 Anti-Anxiety Agents Phase 4
35 Psychotropic Drugs Phase 4
36 GABA Modulators Phase 4
37 Anesthetics, Inhalation Phase 4
38 Anti-Allergic Agents Phase 4
39 Norgestimate, ethinyl estradiol drug combination Phase 4
40 Anti-Infective Agents, Local Phase 4
41 cadexomer iodine Phase 4
42 Carbonic Anhydrase Inhibitors Phase 4
43 Gastrointestinal Agents Phase 4
44 Hormones Phase 4
45 Antineoplastic Agents, Hormonal Phase 4
46 Antiemetics Phase 4
47 Hormone Antagonists Phase 4
48 Dermatologic Agents Phase 4
49 glucocorticoids Phase 4
50 Anti-Inflammatory Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 182)
# Name Status NCT ID Phase Drugs
1 Intra Ocular Pressure After I-gel and Supreme Insertion Unknown status NCT02508181 Phase 4
2 Clinical Study on the Effects of Propofol for Treatment on Emergence Agitation After Sevoflurane Anesthesia in Pediatric Strabismus Surgery Unknown status NCT02738814 Phase 4 propofol
3 Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease Unknown status NCT02339142 Phase 4 intravenous corticosteroids (methylprednisolone)
4 The Impact of Botulinum Toxin Injection in the Frontalis on Brow Height and Morphology: A Randomized Trial Unknown status NCT03186001 Phase 4 Abobotulinum toxin A
5 Intranasal Dexmedetomidine Versus Intranasal Midazolam-ketamine Combination for Premedication of Pediatric Patients Undergoing Strabismus Surgery Completed NCT02072083 Phase 4 Dexmedetomidine;Ketamine
6 Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery Completed NCT01901588 Phase 4 Dexmedetomidine
7 The Effect of Anaesthesia Depth on Oculo-cardiac Reflex in Strabismus Surgery Completed NCT02379546 Phase 4 Desflurane
8 The Effect of Penehyclidine on Postoperative Nausea and Vomiting After Strabismus Surgery Completed NCT04054479 Phase 4 Penehyclidine;normal saline
9 Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery (Topical Rimexolone Versus Topical Dexamethasone and Topical Fluorometholone) Completed NCT02816905 Phase 4 0.1 % Dexamethasone;0.1% Fluorometholone;1% Rimexolone
10 Prospective, Randomized, Double-blind Comparison of 5 % Against 1.25 % Povidone-iodine Solution as Preoperative Antisepsis for Strabismus Surgery in Young Children Completed NCT00461656 Phase 4 Preoperative conjunctival irrigation with 5% or 1.25% PI
11 Surgery Associated to Intraoperative Botulinum Toxin A for Large Angle Horizontal Strabismus: a Pilot Study Completed NCT01460355 Phase 4 Botulinum Toxin Type A;saline solution
12 The Effect of Povidone-iodine Ophthalmic Surgical Prep Solution on Respiration in Children Undergoing Strabismus Surgery With General Anesthesia. Completed NCT03349515 Phase 4 Provodine-Iodine Solution;Group B will receive three drops in each eye of ophthalmic balanced salt solution.
13 Dexmedetomidine Versus Midazolam Premedication on Emergence Agitation After Strabismus Surgery in Children Completed NCT01895023 Phase 4 Dexmedetomidine;Midazolam;Saline
14 Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome Completed NCT01312402 Phase 4 topical brinzolamide 1% in 5mL ophthalmic medication;Placebo in 5 mL dispenser
15 Measuring the Functional Effects of Botox on the Brain Using MR Spectroscopy and fMRI Completed NCT03373162 Phase 4 onabotulinumtoxinA
16 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
17 The Effect of Slanted Recession of Horizontal Muscle on Horizontal Strabismus With Abnormal Accommodative Convergence /Accommodation Ratio (AC/A) Unknown status NCT03555045 Phase 2, Phase 3
18 Vision In Preschoolers Study (VIP Study) Unknown status NCT00038753 Phase 3
19 Comparison of Efficacy of 250 Units Versus 500 Units of Botulinum Toxin in the Treatment of Refractory Vaginismus Unknown status NCT00638066 Phase 3 botulinum toxin;botulinum toxin A
20 A Trial of Bifocals in Myopic Children With Esophoria Unknown status NCT00000128 Phase 3
21 A Multicenter, Randomized, Evaluator-masked, Parallel-group, Non-treatment-controlled Study Followed by an Open-label Study to Evaluate Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus Completed NCT01584843 Phase 3 GSK1358820
22 The Prism Adaptation Study (PAS) Completed NCT00000121 Phase 3
23 Effects of Vertical Prism on the Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria: A Randomized, Double-blinded, Placebo-controlled, Cross-over Study Completed NCT00785135 Phase 3
24 Effect of Intravenous Fluid Therapy on Postoperative Vomiting in Children Undergoing Otorhinolaryngological Surgery Completed NCT01575600 Phase 3
25 Amblyopia Treatment Study Completed NCT00001864 Phase 3 Atropine
26 Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity Completed NCT01203436 Phase 2, Phase 3
27 A Randomized Trial Comparing Part-time Versus Full-time Patching for Severe Amblyopia Completed NCT00094744 Phase 3
28 Efficacy and Safety of Xeomin for the Treatment of Notalgia Paresthetica Completed NCT01098019 Phase 3 Xeomin;Placebo / Xeomin
29 A Randomized Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children 3 to <7 Years Old Completed NCT00091923 Phase 3
30 Amblyopia Treatment Study: Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia Completed NCT00000170 Phase 3 Atropine
31 Bupivacaine Injection of Eye Muscles to Treat Strabismus Recruiting NCT01616108 Phase 2, Phase 3 Bupivacaine
32 Prospective, Double-blind Study Comparing Palonosetron and Dexamethasone in the Prophylaxis of Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery Recruiting NCT04060771 Phase 3 Palonosetron;Dexamethasone
33 A Pragmatic, Randomized, Non-inferiority Trial Comparing the Effectiveness of Botulinum Toxin-based Treatment With Conventional Strabismus Surgery in Acquired Esotropia. Recruiting NCT03459092 Phase 3 Botulinum toxin type A
34 Use of Botulinum Toxin (BTX) for the Treatment of Peripheral Painful Traumatic Trigeminal Neuropathy (PPTTN) Recruiting NCT03555916 Phase 3 BOTOX®, Allergan;Placebo
35 A 48-Week Prospective, Double-Blinded, Randomized, Cross-over Design in Multicenter Study of 250 Unit of Dysport Versus 50 Unit of Neuronox Injection For Cervical Dystonia in Thai Patients Enrolling by invitation NCT03805152 Phase 3 Neuronox(R);Dysport (R)
36 Comparison of Medial Rectus Resection and Plication in Exotropic Patients Not yet recruiting NCT03768362 Phase 2, Phase 3
37 A Randomized Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia in Children 7 to <13 Years Old Terminated NCT00587171 Phase 3
38 Grading Versus Classic Inferior Oblique Anterior Transposition in Patient With Asymmetric Dissociated Vertical Deviation Unknown status NCT03135938 Phase 1, Phase 2
39 ASIS for Enbrel in Plaque Psoriasis Unknown status NCT02112097 Phase 1, Phase 2 Gadolinium;Gadolinium;Gadolinium;Efficacy of Enbrel subcutaneously at Week 12;Efficacy of Enbrel subcutaneously at Week 24;Efficacy of Enbrel subcutaneously at Week 36;Efficacy of Enbrel subdermally at Week 12;Efficacy of Enbrel subdermally at Week 24;Efficacy of Enbrel subdermally at Week 36;PASI 75 n(%) subcutaneously at Week 12;PASI 75 n(%) subcutaneously at Week 24;PASI 75 n(%) subcutaneously at Week 36;PASI 75 n(%) subdermally at Week 12;PASI 75 n(%) subdermally at Week 24;PASI 75 n(%) subdermally at Week 36;Adverse Reactions of Enbrel subcutaneously;Adverse Reactions of Enbrel subdermally at Week 36;Gadolinium;Gadolinium;Gadolinium
40 phase2 Study of Prevention of Complications of Strabismus Surgery Completed NCT00478907 Phase 2 KETAMINE, PROPOFOL, THIOPENTAL
41 Horizontal Rectus Tenotomy in the Treatment of Congenital Nystagmus Completed NCT00001866 Phase 2
42 Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants Completed NCT00349726 Phase 2 Inositol lower volume;Inositol higher volume;Placebo lower volume;Placebo higher volume
43 Phase II Randomized, Double-Masked, Placebo-Controlled, Safety, Pharmacokinetic, and Dose-Ranging Study of Multiple Doses of Inositol in Premature Infants Completed NCT01030575 Phase 2 Inositol lower volume;Inositol mid-level volume;Inositol high volume;Placebo low volume
44 Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity (ROP): A Pilot, Randomized and Prospective Study. Completed NCT01238471 Phase 1, Phase 2 propranolol;sucrose 5%
45 Effect of Intravenous Nalbuphine on Emergence Agitation in Children Undergoing Repair of Rupture Globe Recruiting NCT03470077 Phase 2 IV nalbuphine 0.1 mg/kg with induction of anesthesia.;IV nalbuphine 0.1 mg/kg at the end of surgery.
46 Randomized Study of Non-surgical Treatment Versus Observation in Asian Children With Intermittent Exotropia Terminated NCT01267500 Phase 2
47 The Effect of Vision Therapy/Orthoptic on Motor & Sensory Status of the 3 to 7 Unknown status NCT00917982 Phase 1
48 Monovision for Treatment of Diplopia Completed NCT01426672 Phase 1
49 Investigation of Visual Plasticity by a Direct Current Stimulation of Occipital Cortex in Adult Amblyopia Completed NCT00097162 Phase 1
50 Dichoptic Virtual Reality Therapy for Amblyopia in Adults Terminated NCT02246556 Phase 1

Search NIH Clinical Center for Strabismus

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Botulinum Toxin Type A
Demecarium
demecarium bromide

Genetic Tests for Strabismus

Genetic tests related to Strabismus:

# Genetic test Affiliating Genes
1 Susceptibility to Strabismus 29

Anatomical Context for Strabismus

MalaCards organs/tissues related to Strabismus:

40
Eye, Testes, Thyroid, Cortex, Brain, Retina, Bone

Publications for Strabismus

Articles related to Strabismus:

(show top 50) (show all 11287)
# Title Authors PMID Year
1
The genetics of strabismus. 56 61
15342692 2004
2
A strabismus susceptibility locus on chromosome 7p. 61 56
14519848 2003
3
Genetics of isolated and syndromic strabismus: facts and perspectives. 61 56
12221494 2002
4
The heritability of strabismus. 61 56
7953247 1994
5
Genetic analysis of human visual parameters in populations with varying incidences of strabismus. 56 61
4424621 1974
6
Cyclic strabismus--a case study. 61 56
4706089 1973
7
[On the heredity of strabismus concomitans]. 61 56
5624276 1967
8
Inheritance of congenital esotropia. 56
3590483 1986
9
Heredity in microtropia. 56
5783746 1969
10
Clock-mechanism esotropia in children. Alternate-day squint. 56
4967500 1968
11
GPR143 mutational analysis in two Italian families with X-linked ocular albinism. 61 54
19604113 2009
12
Association of syndromic mental retardation with an Xq12q13.1 duplication encompassing the oligophrenin 1 gene. 61 54
18512229 2008
13
Strabismus in unicoronal synostosis: ipsilateral or contralateral? 61 54
17538304 2007
14
Differential effects of FGFR2 mutation in ophthalmic findings in Apert syndrome. 61 54
17251833 2007
15
Ocular phenotype correlations in patients with TWIST versus FGFR3 genetic mutations. 61 54
17070479 2006
16
Identification of three novel OA1 gene mutations identified in three families misdiagnosed with congenital nystagmus and carrier status determination by real-time quantitative PCR assay. 61 54
12515581 2003
17
Molecular cloning and characterization of Strabismus 2 (STB2). 54 61
11956595 2002
18
New insights into ocular albinism type 1 (OA1): Mutations and polymorphisms of the OA1 gene. 61 54
11793467 2002
19
Severe neural tube defects in the loop-tail mouse result from mutation of Lpp1, a novel gene involved in floor plate specification. 54 61
11709546 2001
20
Ocular albinism type 1: more than meets the eye. 61 54
11549106 2001
21
Mucolipidosis type IV. 54 61
11461186 2001
22
Cloning of the gene encoding a novel integral membrane protein, mucolipidin-and identification of the two major founder mutations causing mucolipidosis type IV. 54 61
11013137 2000
23
Oa1 knock-out: new insights on the pathogenesis of ocular albinism type 1. 54 61
11092754 2000
24
Identification of the gene causing mucolipidosis type IV. 61 54
10973263 2000
25
Ocular anterior chamber dysgenesis in craniosynostosis syndromes with a fibroblast growth factor receptor 2 mutation. 54 61
10406670 1999
26
The thyrotropin receptor in thyroid eye disease. 61 54
9623732 1998
27
Strabismus in Williams syndrome. 61 54
7503839 1995
28
Cloning of a human homologue of the Xenopus laevis APX gene from the ocular albinism type 1 critical region. 61 54
7795590 1995
29
Molecular characterization of SLC24A5 variants and evaluation of Nitisinone treatment efficacy in a zebrafish model of OCA6. 61
32274888 2020
30
Consecutive strabismus after infantile nystagmus syndrome surgery and potential risk factors. 61
32307586 2020
31
Three-dimensional characterisation of the globe position in the orbit. 61
32140924 2020
32
The 3-year outcomes of corneal tattooing for severely disfigured corneas. 61
32297049 2020
33
Case 278: Mutation in ROBO3 Gene-Horizontal Gaze Palsy and Progressive Scoliosis. 61
32421468 2020
34
Morphological Differences in the Inferior Oblique Muscles from Subjects with Over-elevation in Adduction. 61
32539136 2020
35
Ophthalmologic Findings in Fetal Alcohol Spectrum Disorders - A Cohort Study From Childhood to Adulthood. 61
31926885 2020
36
Factors associated with ocular adverse event after immune checkpoint inhibitor treatment. 61
32556494 2020
37
A Novel Missense Mutation in Human Receptor Roundabout-1 (ROBO1) Gene Associated with Pituitary Stalk Interruption Syndrome 61
31448886 2020
38
MAST1 variant causes mega-corpus-callosum syndrome with cortical malformations but without cerebellar hypoplasia. 61
32198973 2020
39
Two cases of 16q12.1q21 deletions and refinement of the critical region. 61
32045705 2020
40
Heavy Eye Syndrome: Myopia Induced Strabismus. 61
32522490 2020
41
Diplopia and Strabismus After Corneal Refractive Surgery. 61
31808933 2020
42
Bupivacaine injection for comitant horizontal strabismus: clinical and radiological results. 61
32049160 2020
43
Simultaneous Bilateral Pediatric and Juvenile Cataract Surgery Under General Anesthesia: Outcomes and Safety. 61
31945328 2020
44
Effect of unilateral vertical transposition of the horizontal rectus muscles on vertical strabismus. 61
32551994 2020
45
Pseudostrabismus in the First Year of Life and the Subsequent Diagnosis of Strabismus. 61
32533950 2020
46
Intraocular pressure elevation associated with blood in Schlemm's canal after strabismus surgery. 61
32195447 2020
47
Alveolar soft part sarcoma of the lateral rectus muscle: Suture technique to prevent postoperative strabismus. 61
32322745 2020
48
Keratopigmentation combined with strabismus surgery to restore cosmesis in eyes with disabling corneal scarring and squint. 61
31527061 2020
49
One-Month Postoperative Horizontal Strabismus Surgery Outcomes Using Adjustable and Nonadjustable Sutures. 61
32511075 2020
50
Differences of a Single Injection of Botulinum Toxin A between Infantile and Nonaccommodative Esotropia. 61
32511074 2020

Variations for Strabismus

ClinVar genetic disease variations for Strabismus:

6 (show top 50) (show all 54) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 DHX30 NM_138615.3(DHX30):c.1685A>G (p.His562Arg)SNV Pathogenic 402130 rs1060499733 3:47888247-47888247 3:47846757-47846757
2 FOXG1 NM_005249.5(FOXG1):c.624C>A (p.Tyr208Ter)SNV Pathogenic 453289 rs267606826 14:29237109-29237109 14:28767903-28767903
3 POGZ NM_015100.4(POGZ):c.2771del (p.Pro924fs)deletion Pathogenic 523510 rs1553212868 1:151378740-151378740 1:151406264-151406264
4 subset of 24 genes: MAGEL2 , SNURF , UBE3A GRCh37/hg19 15q11.2-13.1(chr15:23810397-29213787)copy number gain Pathogenic 523251 15:23810397-29213787
5 subset of 22 genes: FLCN , RAI1 GRCh37/hg19 17p11.2(chr17:16936603-18184130)copy number loss Pathogenic 523258 17:16936603-18184130
6 CLUH , METTL16 , PAFAH1B1 , RAP1GAP2 GRCh37/hg19 17p13.3(chr17:2339561-2826073)copy number loss Pathogenic 523261 17:2339561-2826073
7 ADGRG1 NM_201525.4(ADGRG1):c.1583dup (p.Ala529fs)duplication Pathogenic 544681 rs1567815105 16:57694706-57694707 16:57660794-57660795
8 TMCO1 NM_019026.4(TMCO1):c.616C>T (p.Arg206Ter)SNV Pathogenic 598963 rs765379963 1:165712409-165712409 1:165743172-165743172
9 MED13L NM_015335.4(MED13L):c.1971del (p.Asp657fs)deletion Pathogenic 523512 rs1555247805 12:116446247-116446247 12:116008442-116008442
10 SLC2A1 NM_006516.4(SLC2A1):c.732_735GAAG[1] (p.Glu246fs)short repeat Pathogenic 812757 1:43395392-43395395 1:42929721-42929724
11 SIL1 NC_000005.10:g.139189727_139201554deldeletion Pathogenic 812923 5:138525416-138537243
12 TYR NM_000372.5(TYR):c.265T>C (p.Cys89Arg)SNV Pathogenic 3781 rs28940877 11:88911386-88911386 11:89178218-89178218
13 STXBP1 NM_003165.4(STXBP1):c.364C>T (p.Arg122Ter)SNV Pathogenic 198157 rs794727792 9:130423419-130423419 9:127661140-127661140
14 PCDH19 NM_001184880.2(PCDH19):c.1091dup (p.Tyr366fs)duplication Pathogenic 206353 rs758946412 X:99662504-99662505 X:100407506-100407507
15 GNB1 NM_002074.5(GNB1):c.239T>C (p.Ile80Thr)SNV Pathogenic 208722 rs752746786 1:1737942-1737942 1:1806503-1806503
16 MED13L t(12;19)(q24.21;q12)Translocation Pathogenic 218934
17 NALCN NM_052867.4(NALCN):c.3390G>A (p.Pro1130=)SNV Pathogenic 222073 rs869312873 13:101742197-101742197 13:101089846-101089846
18 SPART NM_015087.5(SPART):c.1450dup (p.Thr484fs)duplication Pathogenic 183277 rs730882198 13:36888396-36888397 13:36314259-36314260
19 GNB1 NM_002074.5(GNB1):c.233A>G (p.Lys78Arg)SNV Pathogenic 224714 rs869312823 1:1737948-1737948 1:1806509-1806509
20 46;XY;t(1;5)(p35.3;q31.3)dnTranslocation Pathogenic 267817
21 46;XX;t(3;12)(q13.2;q14)dnTranslocation Pathogenic 267821
22 46;XY;t(6;11)(p12.3;p14.2)dnTranslocation Pathogenic 268006
23 46;XX;t(2;10)(q22;22.3)dnTranslocation Pathogenic 268036
24 46;XX;ins(2;9)(q24.3;p22.1p24.3)dnTranslocation Pathogenic 268044
25 46;X;t(X;3)(p21.3;p25.1)dnTranslocation Pathogenic 268009
26 MPP4 NM_033066.3(MPP4):c.946T>C (p.Trp316Arg)SNV Pathogenic 375383 rs1057519443 2:202539978-202539978 2:201675255-201675255
27 DHX30 NM_138615.3(DHX30):c.1478G>A (p.Arg493His)SNV Pathogenic 375374 rs1057519436 3:47888040-47888040 3:47846550-47846550
28 KIF7 NM_198525.3(KIF7):c.434A>C (p.Tyr145Ser)SNV Pathogenic/Likely pathogenic 374124 rs758361736 15:90193067-90193067 15:89649836-89649836
29 GALC NM_000153.4(GALC):c.850G>A (p.Gly284Ser)SNV Pathogenic/Likely pathogenic 374024 rs377274761 14:88434737-88434737 14:87968393-87968393
30 GNB1 NM_002074.5(GNB1):c.284T>C (p.Leu95Pro)SNV Pathogenic/Likely pathogenic 224716 rs869312824 1:1736004-1736004 1:1804565-1804565
31 GNB1 NM_002074.5(GNB1):c.228T>G (p.Asp76Glu)SNV Pathogenic/Likely pathogenic 224712 rs869312822 1:1737953-1737953 1:1806514-1806514
32 NFIX NM_002501.4(NFIX):c.440G>A (p.Gly147Glu)SNV Likely pathogenic 627622 rs1568269273 19:13136247-13136247 19:13025433-13025433
33 DMBX1 NM_172225.2(DMBX1):c.352C>T (p.Arg118Trp)SNV Likely pathogenic 183286 rs730882203 1:46976625-46976625 1:46510953-46510953
34 RSRC2 NM_023012.6(RSRC2):c.425G>A (p.Arg142Gln)SNV Likely pathogenic 242899 rs752134549 12:123001951-123001951 12:122517404-122517404
35 subset of 172 genes: ARCN1 , HMBS , KMT2A deletion Likely pathogenic 812956 11:114433313-131230466
36 CACNA1A NM_001127221.1(CACNA1A):c.5422G>T (p.Ala1808Ser)SNV Likely pathogenic 523409 rs1555736565 19:13341005-13341005 19:13230191-13230191
37 QARS1 NM_005051.3(QARS1):c.1430A>G (p.Tyr477Cys)SNV Likely pathogenic 598953 rs1172486173 3:49137039-49137039 3:49099606-49099606
38 QARS1 NM_005051.3(QARS1):c.1132C>T (p.Arg378Cys)SNV Likely pathogenic 598952 rs185476065 3:49137655-49137655 3:49100222-49100222
39 TYR NM_000372.5(TYR):c.1352A>G (p.Tyr451Cys)SNV Likely pathogenic 523363 rs376823382 11:89018108-89018108 11:89284940-89284940
40 GALC NM_000153.4(GALC):c.196G>A (p.Ala66Thr)SNV Likely pathogenic 374023 rs1057518843 14:88454867-88454867 14:87988523-87988523
41 46;XX;t(6;21)(q14;q21)dnTranslocation Likely pathogenic 268025
42 FOXP1 NM_032682.6(FOXP1):c.1396C>G (p.Pro466Ala)SNV Likely pathogenic 374144 rs1057518926 3:71026826-71026826 3:70977675-70977675
43 SOX5 NM_006940.6(SOX5):c.482-2A>CSNV Likely pathogenic 374026 rs1057518845 12:23908660-23908660 12:23755726-23755726
44 SOX3 NM_005634.2(SOX3):c.735_737dup (p.Ala248dup)duplication Conflicting interpretations of pathogenicity 95305 rs398124211 X:139586488-139586489 X:140504323-140504324
45 NF1 NM_000267.3(NF1):c.1987G>A (p.Gly663Arg)SNV Uncertain significance 184278 rs140653372 17:29552254-29552254 17:31225236-31225236
46 46;XX;inv(5)(q14q33)dninversion Uncertain significance 268008
47 46;XX;inv(14)(q24.1q32.1)dninversion Uncertain significance 267889
48 GFOD1 , MCUR1 , NOL7 , PHACTR1 , RANBP9 , RNF182 , SIRT5 , TBC1D7 GRCh37/hg19 6p24.1-23(chr6:12536624-13968949)copy number gain Uncertain significance 523282 6:12536624-13968949
49 LMBR1 , RNF32 GRCh37/hg19 7q36.3(chr7:156333296-156556779)copy number gain Uncertain significance 523286 7:156333296-156556779
50 LMBR1 , MNX1 , NOM1 GRCh37/hg19 7q36.3(chr7:156656444-156866708)copy number gain Uncertain significance 523287 7:156656444-156866708

Copy number variations for Strabismus from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 195555 5 152100000 155600000 Deletion AK124699 strabismus
2 195560 5 152100000 155600000 Deletion C5ORF21 strabismus
3 195565 5 152100000 155600000 Deletion C5ORF3 strabismus
4 195570 5 152100000 155600000 Deletion GALNT10 strabismus
5 195575 5 152100000 155600000 Deletion HAND1 strabismus
6 195580 5 152100000 155600000 Deletion MFAP3 strabismus
7 195585 5 152100000 155600000 Deletion NR2F1 strabismus
8 195590 5 152100000 155600000 Deletion SAP30L strabismus

Expression for Strabismus

Search GEO for disease gene expression data for Strabismus.

Pathways for Strabismus

GO Terms for Strabismus

Sources for Strabismus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....